---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-030407"
form_type: "8-K"
ticker: "PMVP"
cik: "0001699382"
company_name: "PMV Pharmaceuticals, Inc."
filed_at: "2025-03-03T23:59:59+00:00"
generated_at: "2026-05-25T18:44:34.331017+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# PMV Pharma reports FY2024 net loss of $58.7M; cash runway to end of 2026; Phase 2 interim data mid-2025

## Summary
- Net loss of $58.7M for FY2024, compared to $69.0M in FY2023; no revenue.
- Cash, cash equivalents & marketable securities of $183.3M as of Dec 31, 2024; provides cash runway to end of 2026.
- Phase 2 PYNNACLE trial enrollment on track; interim analysis data expected mid-2025; NDA submission anticipated by end of 2026.
- Discontinued enrollment in Phase 1b combination arm of rezatapopt with pembrolizumab due to lack of clinically meaningful benefit.
- Enrollment commenced in investigator-initiated Phase 1b study of rezatapopt in relapsed/refractory AML/MDS with TP53 Y220C mutation.

## SEC filing metadata
- accession: 0000950170-25-030407
- form_type: 8-K
- ticker: PMVP
- cik: 0001699382
- company_name: PMV Pharmaceuticals, Inc.
- filed_at: 2025-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1699382/000095017025030407/0000950170-25-030407-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1699382/000095017025030407/pmvp-20250303.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-030407
- JSON: https://secwatch.observer/filing/0000950170-25-030407.json
- Plain text: https://secwatch.observer/filing/0000950170-25-030407.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.